万泰生物：部分募集资金投资项目延期

Core Viewpoint - The company has announced a delay in the completion of its second-phase expansion project for the nine-valent cervical cancer vaccine, pushing the expected operational date from December 2025 to December 2026 [1] Funding and Financials - The initial planned investment for the project was 1.1 billion yuan, which has been adjusted to approximately 1.060 billion yuan [1] - The funding source for this project will continue to be from non-public stock issuance [1] Project Requirements and Delays - The delay is primarily due to the need to complete processes such as process validation, comparability studies, and stability studies as required by regulatory authorities [1] - Additional registration documentation for the new production line must be submitted and approved before commercial production can commence [1] Impact on Operations - The delay is a cautious decision aimed at ensuring the quality of project construction and improving the efficiency of fund utilization [1] - There will be no changes to the implementation entity, location, or investment scale, and the use of raised funds will remain unchanged [1] - The delay is not expected to negatively impact the company's main business or financial status and is aligned with the company's long-term development strategy [1]